Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Jones Financial Companies Lllp
Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
MoneyWeek on MSN2d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
The stock's fall snapped a four-day winning streak.
Vertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF
Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment
Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Barchart on MSN4d
Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...
Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...
3 Magnificent Growth Stocks to Buy in March
It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...